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Editorial on the Research Topic
Ovarian Ageing: Pathophysiology and Recent Development of Maintaining Ovarian Reserve
Increased understanding of ovarian aging is essential in the modern world. Ages at menopause
have remained stable at average of 51 years in Europe and 49 years in China, with some evidence
that environmental xenobiotic toxicity is reducing reproductive lifespans for women. Most women
have 12% of their follicle pool remaining at age 30, falling to 3% at age 40 years. However, age
at motherhood has increased steadily over the last few decades, with, for example, birth rates
for ages 35–39 and 40–44 years more than doubling in the United States of America between
1990 and 2015. Since 1970 the average maternal age at birth in most OECD countries has
increased by 2–5 years. The adverse effects of increased maternal age on reproductive outcomes
are well-known, with maternal age being the strongest predictor of in vitro fertilization (IVF)
success, and a decline in female fecundity with age associated with a reduction in oocyte quality
and an increased risk of miscarriage. Hence there is a clear potential conflict between the biology of
reproduction working against motherhood later in life, and the societal expectation of motherhood
at an age convenient for the mother in terms of education, career, relationship, and family
considerations. The postponement of starting a family therefore has implications on the ability of
women to conceive and parents to produce additional offspring. Societal changes in terms of policy
interventions regarding career breaks and higher institutional gender equity can be useful, as can
efforts to counter scarce information or poor understanding such as the diffuse idea of omnipotence
of modern medicine. But the burden of effort in maintaining ovarian reserve, and hence fertility,
remains with academic and clinical teams, working together to optimize fertility outcomes, based
on careful analyses of high-quality data to identify the evidence needed to underpin safe and reliable
clinical practice. It should also be noted that ovarian aging can occur as a result of chemo- and/or
radiotherapies used to treat cancer patients of any age, and hence that the lessons learned from
studies into ovarian aging are useful and applicable not only for spontaneous pregnancies and
assisted conception cycles, but also oncofertility-related pregnancies.
We asked the contributors of this Research Topic to provide useful insights into the underlying
mechanisms of fertility, with particular emphasis on endocrine factors. Whilst animal models were
not excluded, we encouraged submissions based on human studies and that therefore have direct
relevance to the unique challenges facing our species. The result is a varied yet comprehensive
collection of five articles and two abstracts.
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Follicle–stimulating hormone (FSH) was identified in the
1980s as an ovarian factor that reduced gonadotropin-releasing
hormone (GnRH)-induced luteinizing hormone (LH) secretion,
and swiftly became the standard approach used to stimulate
gonadal function in hypogonadotropic hypogonadism. FSH
entered clinical use in controlled ovarian stimulation as
a stimulant for follicular growth in assisted reproduction.
However, robust evidence that supports the clinical use of FSH
is still sparse. Abbara, Patel et al. designed and reported on a
study aimed to evaluate FSH requirements for follicular growth
during controlled ovarian stimulation. Initial recombinant FSH
(rFSH) doses were adjusted for body weight and matched to
the follicle sizes at time of oocyte maturation trigger. Their key
finding is that an insufficient weight-adjusted dose (i.e., requiring
significant dose increase after an initial dose) led to variability
in follicle sizes, hence to fewer mature oocytes being obtained
with clear negative impact on the chances of a live birth from
the cycle. Given that the literature suggests an upper threshold
exists for useful FSH dosing, this study provides IVF practitioners
with lower limits in addition to upper limits for optimal dosing
regimen for individual cycles. The crucial relationship between
follicle profile at time of trigger and mature oocytes obtained was
established by the same research group in 2018.
A well-established issue with IVF is that standard in-vitro
culture conditions exert oxidative stress, with the presence
reactive oxygen species (ROS) resulting in an imbalance between
oxidants and antioxidants, potentially leading to structural and
functional changes in cells. Sasaki et al. reviewed the underlying
mechanisms of the age-related decline in oocyte quality, with
specific focus on oxidative stress. They identify the primary
mechanisms involved, describe the vulnerability of oocytes to
these mechanisms, and suggest possible therapeutic strategies to
reduce the adverse effects of oxidative stress on ovarian aging.
The utility of growth hormone (GH) in assisted conception
is extensively reviewed in seperate articles by Blumenfeld and
Hart with both authors identifying the lack of power in existing
studies that reduces our confidence in the claimed benefits of
routine GH treatment, even for those cases that are classified
as poor responding according to the Bologna definition. Hart
emphasizes the key point that no meta-analysis has shown that
the use of GH increases the chances of live birth, which is, of
course, the primary desired outcome. His detailed identification
and description of the key literature in this area highlights the use
of GH as one of several “folklore” methods in assisted conception,
used in line with prevailing clinical procedural norms, rather
than used as result of detailed supporting evidence. Blumenfeld
makes many of similar deductions, but additionally addresses the
issue of what treatments should be used if GH is found not to be
suitable. Interestingly, GH is not ruled out with the suggestion
that it may be effective in exceptional and restricted cases—poor
ovarian response patients with borderline GH deficiency.
Kisspeptins are proteins encoded by the KISS1 gene in
humans. KISS1 was originally identified as a human metastasis
suppressor gene. Kisspeptins were later found to have an
important role in initiating secretion of GnRH at puberty, and as
a method to stimulate ovulation in IVF cycles leading in principle
to a more physiological increase in reproductive hormones
and oocyte maturation during IVF treatment. Trevisan et al.
(accepted) performed a detailed and comprehensive comparative
analysis of KISS1 polymorphisms with respect to key factors
that influence the prospects of live birth, finding that the KISS1
rs1132506 polymorphism was associated with decreased AMH
levels, increased estradiol and prolactin levels and decreased
number of mature oocytes and embryos.
Amenorrhea is a key characteristic of perimenopause and
the aging ovary. Anti-Mullerian Hormone (AMH) is now
accepted as a biomarker for both ovarian activity—and hence
remaining ovarian reserve—and as a diagnostic predictor of
polycystic ovarian syndrome (PCOS). Abbara, Eng et al. report
that AMH is a strong predictor for menstrual disturbance
due to PCOS, and furthermore that the risk of menstrual
disturbance increases with elevation in serum AMH. In
addition to these main findings, the authors show that high
AMH leads to more LH in follicular phase gonadotropin
levels, commensurate with an increase in GnRH pulsatility.
Study participants with more LH-predominant gonadotropin
secretion also had increased rates of menstrual disturbance.
These findings increase our understanding of the complex and
dynamic endocrine and paracrine milieu associated with the
aging ovary.
CONCLUDING REMARKS
Taken together, the research studies and reviews contained in
this Research Topic provide clear and detailed insights into
several fundamental aspects of the important and challenging
undertaking of maximizing the chances of safe live births for the
increasing number of women seeking to delay motherhood. The
results are useful to clinical teams working in assisted conception,
and also indicate to research groups the challenges that remain to
gain a fuller understanding of ovarian aging.
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